Abiopharma

🔍 ENGEL JOHN (Executive)

Company: WESCO INTERNATIONAL INC (WCC)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Acquired 72,541 shares of Common Stock at $54.64 per share (Direct)
  Date: 2026-05-05 | Code: M | equity_swap_involved: false | shares_owned_after: 551,486.74 | transaction_form_type: 4
• Acquired 92,893 shares of Common Stock at $48.32 per share (Direct)
  Date: 2026-05-05 | Code: M | equity_swap_involved: false | shares_owned_after: 644,379.74 | transaction_form_type: 4
• Sold 24,109 shares of Common Stock at $350.59 per share (Direct)
  Date: 2026-05-05 | Code: D | equity_swap_involved: false | shares_owned_after: 620,270.74 | transaction_form_type: 4
• Sold 61,885 shares of Common Stock at $350.59 per share (Direct)
  Date: 2026-05-05 | Code: F | equity_swap_involved: false | shares_owned_after: 558,385.74 | transaction_form_type: 4
• Sold 471 shares of Common Stock at $353.74 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 557,914.74 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,949 shares of Common Stock at $355.34 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 551,965.74 | transaction_form_type: 4 | Footnotes: F2
• Sold 6,188 shares of Common Stock at $356.24 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 545,777.74 | transaction_form_type: 4 | Footnotes: F3
• Sold 21,074 shares of Common Stock at $357.36 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 524,703.74 | transaction_form_type: 4 | Footnotes: F4
• Sold 4,064 shares of Common Stock at $358.39 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 520,639.74 | transaction_form_type: 4 | Footnotes: F5
• Sold 10,134 shares of Common Stock at $359.43 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 510,505.74 | transaction_form_type: 4 | Footnotes: F6
• Sold 18,103 shares of Common Stock at $360.43 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 492,402.74 | transaction_form_type: 4 | Footnotes: F7
• Sold 12,546 shares of Common Stock at $361.01 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 479,856.74 | transaction_form_type: 4 | Footnotes: F8
• Sold 911 shares of Common Stock at $362.43 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 478,945.74 | transaction_form_type: 4 | Footnotes: F9
• Sold 72,541 shares of Stock Appreciation Rights at $54.64 per share (Derivative)
  Date: 2026-05-05 | Code: M | Expires: 2029-02-13 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F10
• Sold 92,893 shares of Stock Appreciation Rights at $48.32 per share (Derivative)
  Date: 2026-05-05 | Code: M | Expires: 2030-02-13 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F11

Footnotes:

• F1: Represents weighted average sale price. These shares were sold in multiple transactions at prices ranging from $353.67 - $353.93. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
• F2: Represents weighted average sale price. These shares were sold in multiple transactions at prices ranging from $354.82 - $355.79. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
• F3: Represents weighted average sale price. These shares were sold in multiple transactions at prices ranging from $355.84 - $356.81. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
• F4: Represents weighted average sale price. These shares were sold in multiple transactions at prices ranging from $356.84 - $357.83. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
• F5: Represents weighted average sale price. These shares were sold in multiple transactions at prices ranging from $357.84 - $358.83. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
• F6: Represents weighted average sale price. These shares were sold in multiple transactions at prices ranging from $358.86 - $359.85. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
• F7: Represents weighted average sale price. These shares were sold in multiple transactions at prices ranging from $359.91 - $360.87. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
• F8: Represents weighted average sale price. These shares were sold in multiple transactions at prices ranging from $360.91 - $361.89. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
• F9: Represents weighted average sale price. These shares were sold in multiple transactions at prices ranging from $361.92 - $362.73. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
• F10: The Stock Appreciation Rights became exercisable in three (3) equal, annual installments beginning on the first anniversary of the February 13, 2019 grant date.
• F11: The Stock Appreciation Rights became exercisable in three (3) equal, annual installments beginning on the first anniversary of the February 13, 2020 grant date.